1,3,7-Trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism

Journal of Immunology

Volumn 179, Issue 11, 2007, Pages 7431-7438

  Ohta, Akio ^a,b   Lukashev, Dmitriy ^a,b   Jackson, Edwin K ^c   Fredholm, Bertil B ^d   Sitkovsky, Michail ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; CAFFEINE; GAMMA INTERFERON; INTERLEUKIN 6; LYMPHOTOXIN; LYMPHOTOXIN BETA; TUMOR NECROSIS FACTOR ALPHA; ADENOSINE A2A RECEPTOR; BACTERIAL TOXIN; EXOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHODIESTERASE INHIBITOR; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BLOOD SAMPLING; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; FEMALE; FOOD INTAKE; HEPATITIS; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IN VIVO STUDY; INHIBITION KINETICS; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ACUTE DISEASE; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; LIVER; MOUSE MUTANT; PATHOLOGY; TOXIC HEPATITIS;

ACUTE DISEASE; ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; CAFFEINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXOTOXINS; FEMALE; HEPATITIS, TOXIC; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHODIESTERASE INHIBITORS; RECEPTOR, ADENOSINE A2A; VIRULENCE FACTORS;

EID: 38849133578     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.11.7431     Document Type: Article

References (55)

1. Fredholm, B. B., K. Battig, J. Holmen, A. Nehlig, and E. E. Zvartau. 1999. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51: 83-133.
2. Foukas, L. C., N. Daniele, C. Ktori, K. E. Anderson, J. Jensen, and P. R. Shepherd. 2002. Direct effects of caffeine and theophylline on p110 δ and other phosphoinositide 3-kinases: differential effects on lipid kinase and protein kinase activities. J. Biol. Chem. 277: 37124-37130.
3. Lukashev, D. E., P. T. Smith, C. C. Caldwell, A. Ohta, S. G. Apasov, and M. V. Sitkovsky. 2003. Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. Biochem. Pharmacol. 65: 2081-2090.
4. Huang, S., S. Apasov, M. Koshiba, and M. Sitkovsky. 1997. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90: 1600-1610.
5. + T cells. J. Immunol. 174: 1073-1080.
6. Koshiba, M., H. Kojima, S. Huang, S. Apasov, and M. V. Sitkovsky. 1997. Memory of extracellular adenosine/A2a purinergic receptor-mediated signaling in murine T cells. J. Biol. Chem. 272: 25881-25889.
7. Link, A. A., T. Kino, J. A. Worth, J. L. McGuire, M. L. Crane, G. P. Chrousos, R. L. Wilder, and I. J. Elenkov. 2000. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J. Immunol. 164: 436-442.
8. Cronstein, B. N., L. Daguma, D. Nichols, A. J. Hutchison, and M. Williams. 1990. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J. Clin. Invest. 85: 1150-1157.
9. Okusa, M. D., J. Linden, T. Macdonald, and L. Huang. 1999. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am. J. Physiol. 277: F404-F412.
10. Day, Y. J., M. A. Marshall, L. Huang, M. J. McDuffie, M. D. Okusa, and J. Linden. 2004. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am. J. Physiol. 286: G285-G293.
11. Fozard, J. R., K. M. Ellis, M. F. Villela Dantas, B. Tigani, and L. Mazzoni. 2002. Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur. J. Pharmacol. 438: 183-188.
12. Ohta, A., and M. Sitkovsky. 2001. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414: 916-920.
13. Saadi, S., L. E. Wrenshall, and J. L. Platt. 2002. Regional manifestations and control of the immune system. FASEB J. 16: 849-856.
14. Rudolphi, K. A., P. Schubert, F. E. Parkinson, and B. B. Fredholm. 1992. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci. 13: 439-445.
15. Sitkovsky, M. V., D. Lukashev, S. Apasov, H. Kojima, M. Koshiba, C. Caldwell, A. Ohta, and M. Thiel. 2004. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22: 657-682.
16. Sitkovsky, M. V., and A. Ohta. 2005. The "danger" sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol. 26: 299-304.
17. Decking, U. K., G. Schlieper, K. Kroll, and J. Schrader. 1997. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ. Res. 81: 154-164.
18. Kobayashi, S., H. Zimmermann, and D. E. Millhorn. 2000. Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. J. Neurochem. 74: 621-632.
19. Lawrence, T., D. A. Willoughby, and D. W. Gilroy. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2: 787-795.
20. Tiegs, G., J. Hentschel, and A. Wendel. 1992. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90: 196-203.
21. + T cells for concanavalin A-induced hepatic injury in mice. J. Immunol. 159: 1537-1542.
22. Kaneko, Y., M. Harada, T. Kawano, M. Yamashita, Y. Shibata, F. Gejyo, T. Nakayama, and M. Taniguchi. 2000. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J. Exp. Med. 191: 105-114.
23. Schumann, J., D. Wolf, A. Pahl, K. Brune, T. Papadopoulos, N. van Rooijen, and G. Tiegs. 2000. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am. J. Pathol. 157: 1671-1683.
24. Kusters, S., F. Gantner, G. Kunstle, and G. Tiegs. 1996. Interferon γ plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 111: 462-471.
25. Kusters, S., G. Tiegs, L. Alexopoulou, M. Pasparakis, E. Douni, G. Kunstle, H. Bluethmann, A. Wendel, K. Pfizenmaier, G. Kollias, and M. Grell. 1997. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur. J. Immunol. 27: 2870-2875.
26. Schumann, J., S. Angermuller, R. Bang, M. Lohoff, and G. Tiegs. 1998. Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. J. Immunol. 161: 5745-5754.
27. Faggioni, R., J. Jones-Carson, D. A. Reed, C. A. Dinarello, K. R. Feingold, C. Grunfeld, and G. Fantuzzi. 2000. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor α and IL-18. Proc. Natl. Acad. Sci. USA 97: 2367-2372.
28. Chen, J. F., R. Moratalla, L. Yu, A. B. Martin, K. Xu, E. Bastia, E. Hackett, I. Alberti, and M. A. Schwarzschild. 2003. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology 28: 1086-1095.
29. Frye, R. F., D. D. Stiff, and R. A. Branch. 1998. A sensitive method for the simultaneous determination of caffeine and its dimethyl-xanthine metabolites in human plasma: application to CYP1A2 phenotyping. J. Liquid Chromatogr. Rel. Tech. 21: 1161-1171.
30. Fredholm, B. B., A. P. Ijzerman, K. A. Jacobson, K. N. Klotz, and J. Linden. 2001. International union of pharmacology, XXV: nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53: 527-552.
31. He, P., Y. Noda, and K. Sugiyama. 2001. Suppressive effect of coffee on lipopolysaccharide-induced hepatitis in D-galactosamine-sensitized rats. Biosci. Biotechnol. Biochem. 65: 1924-1927.
32. Nicoletti, F., R. Di Marco, P. Zaccone, A. Salvaggio, G. Magro, K. Bendtzen, and P. Meroni. 2000. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-γ-dependent mechanism. Hepatology 32: 728-733.
33. Louis, H., O. Le Moine, M. O. Peny, E. Quertinmont, D. Fokan, M. Goldman, and J. Deviere. 1997. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology 25: 1382-1389.
34. Gantner, F., S. Kusters, A. Wendel, A. Hatzelmann, C. Schudt, and G. Tiegs. 1997. Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 280: 53-60.
35. Robertson, D., D. Wade, R. Workman, R. L. Woosley, and J. A. Oates. 1981. Tolerance to the humoral and hemodynamic effects of caffeine in man. J. Clin. Invest. 67: 1111-1117.
36. Finn, I. B., and S. G. Holtzman. 1986. Tolerance to caffeine-induced stimulation of locomotor activity in rats. J. Pharmacol. Exp. Ther. 238: 542-546.
37. Johansson, B., V. Georgiev, K. Lindstrom, and B. B. Fredholm. 1997. A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res. 762: 153-164.
38. Rudolphi, K. A., M. Keil, J. Fastbom, and B. B. Fredholm. 1989. Ischaemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci. Lett. 103: 275-280.
39. Bona, E., U. Aden, B. B. Fredholm, and H. Hagberg. 1995. The effect of long term caffeine treatment on hypoxic-ischemic brain damage in the neonate. Pediatr. Res. 38: 312-318.
40. Jacobson, K. A., D. K. von Lubitz, J. W. Daly, and B. B. Fredholm. 1996. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17: 108-113.
41. May, D. C., C. H. Jarboe, A. B. VanBakel, and W. M. Williams. 1982. Effects of cimetidine on caffeine disposition in smokers and nonsmokers. Clin. Pharmacol. Ther. 31: 656-661.
42. Buters, J. T., B. K. Tang, T. Pineau, H. V. Gelboin, S. Kimura, and F. J. Gonzalez. 1996. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics 6: 291-296.
43. Lelo, A., J. O. Miners, R. Robson, and D. J. Birkett. 1986. Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin. Pharmacol. Ther. 39: 54-59.
44. Cook, D. G., J. L. Peacock, C. Feyerabend, I. M. Carey, M. J. Jarvis, H. R. Anderson, and J. M. Bland. 1996. Relation of caffeine intake and blood caffeine concentrations during pregnancy to fetal growth: prospective population based study. BMJ 313: 1358-1362.
45. Smith, J. M., S. Pearson, and V. Marks. 1982. Plasma caffeine concentration in outpatients. Lancet 2: 985-986.
46. Tiffin, P., H. Ashton, R. Marsh, and F. Kamali. 1995. Pharmacokinetic and pharmacodynamic responses to caffeine in poor and normal sleepers. Psychopharmacology 121: 494-502.
47. Klatsky, A. L., and M. A. Armstrong. 1992. Alcohol, smoking, coffee, and cirrhosis. Am. J. Epidemiol. 136: 1248-1257.
48. Klatsky, A. L., M. A. Armstrong, and G. D. Friedman. 1993. Coffee, tea, and mortality. Ann. Epidemiol. 3: 375-381.
49. Corrao, G., A. R. Lepore, P. Torchio, M. Valenti, G. Galatola, A. D'Amicis, S. Arico, and F. di Orio. 1994. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption: a case-control study, Provincial Group for the Study of Chronic Liver Disease. Eur. J. Epidemiol. 10: 657-664.
50. Corrao, G., A. Zambon, V. Bagnardi, A. D'Amicis, A. Klatsky, and Collaborative SIDECIR Group. 2001. Coffee, caffeine, and the risk of liver cirrhosis. Ann. Epidemiol. 11: 458-465.
51. Gallus, S., A. Tavani, E. Negri, and C. La Vecchia. 2002. Does coffee protect against liver cirrhosis? Ann. Epidemiol. 12: 202-205.
52. Tverdal, A., and S. Skurtveit. 2003. Coffee intake and mortality from liver cirrhosis. Ann. Epidemiol. 13: 419-423.
53. Ruhl, C. E., and J. E. Everhart. 2005. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 128: 24-32.
54. Ohta, A., E. Gorelik, S. J. Prasad, F. Ronchese, D. Lukashev, M. K. Wong, X. Huang, S. Caldwell, K. Liu, P. Smith, et al. 2006. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. USA 103: 13132-13137.
55. Thiel, M., A. Chouker, A. Ohta, E. Jackson, C. Caldwell, P. Smith, D. Lukashev, I. Bittmann, and M. V. Sitkovsky. 2005. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol. 3: e174.